TAF4

Across TCGA pan-cancer cohorts, TAF4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAF4 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TAF4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TAF4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and UCEC are the cancer types where TAF4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.972	0.547	.013	9	view →
GBM	OS	Tertile	All	0.566	0.316	.009	4	view →
UCEC	OS	Tertile	All	0.907	1.000	.028	2	view →
CCRCC	DFS	Median	IV	0.749	0.253	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TAF4–LUAD (DFS)

Open the LUAD breakdown →